Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus
Transplant Infectious Disease · 2024-08 · 26 (4)
DOI: 10.1111/tid.14291 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transplant Infectious Disease, online erschienen am 06.05.2024. Verfasst von Abigail M Servais und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical and Nutrition Care, Nebraska Medical Center Omaha, Omaha, Nebraska, USA. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Kidney Transplantation, Antiviral Agents, Valganciclovir. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Background
Valganciclovir prophylaxis against cytomegalovirus (CMV) is recommended for solid organ transplant recipients, but is associated with drawbacks, including expense and leukopenia. Our center adopted a strategy of serial assessment with a CMV‐specific T cell immunity panel (CMV‐TCIP) and cessation of valganciclovir prophylaxis upon demonstration of adequate CD4+ responses in kidney transplant patients at high risk of CMV disease.
Methods
We retrospectively reviewed adult recipients of a kidney or pancreas transplant between August 2019 and July 2021 undergoing serial CMV‐TCIP monitoring. Included patients were considered high risk for CMV, defined by donor positive (D+)/recipient negative (R−) CMV IgG serostatus, or recipient positive (R+) patients who received induction with a lymphocyte‐depleting agent. Prophylaxis was discontinued after a patient's first CMV‐specific CD4+ T cell value of ≥0.20%. Risk of clinically significant CMV infection (csCMVi) in those who underwent early discontinuation of CMV prophylaxis and predictors of CMV T cell immunity were analyzed.
Results
Of 54 included patients, 22 stopped prophylaxis early due to CMV‐specific CD4+ T cell immunity at a median of 4.7 (IQR: 3.8–5.4) months after transplant. No instances of csCMVi were observed in the 22 patients who had prophylaxis discontinued early, of whom 19/22 were CMV R+ and 3/22 were CMV D+/R−. Donor/recipient CMV serostatus was predictive of immunity ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical and Nutrition Care, Nebraska Medical Center Omaha, Omaha, Nebraska, USA.
- University of Nebraska Medical Center College of Pharmacy, Nebraska Medical Center Omaha, Omaha, Nebraska, USA.
- Eurofins Viracor, Lenexa, Kansas, USA.
- Department of Internal Medicine, Division of Nephrology, Nebraska Medical Center, Omaha, Nebraska, USA.
ORCID-Profile: Abigail M Servais
Zitieren
APA
Servais, A. M., McMullen, J. S., Bowen, R., Kleiboeker, S. B., Ulloa, I., Duncan, K., & Miles, C. D. (2024). Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus. Transplant Infectious Disease, 26(4). https://doi.org/10.1111/tid.14291
Vancouver
Servais AM, McMullen JS, Bowen R, Kleiboeker SB, Ulloa I, Duncan K, et al. Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus. Transplant Infectious Disease. 2024;26(4). doi:10.1111/tid.14291
BibTeX
@article{Servais2024,
author = {Servais, Abigail M and McMullen, John S and Bowen, Riley and Kleiboeker, Steven B and Ulloa, Isabelle and Duncan, Kara and Miles, Clifford D},
title = {Tailoring cytomegalovirus prophylaxis based on T cell immunity panel assessment in kidney transplant patients at high risk of cytomegalovirus},
journal = {Transplant Infectious Disease},
year = {2024},
volume = {26},
number = {4},
doi = {10.1111/tid.14291}
}
EUVIMED